PedAM
Pediatric Disease Annotations & Medicines
| Disease | liver disease |
| Phenotype | |hepatitis c |
| Sentences | 69 |
| PubMedID- 25737729 | However, there is no data supporting the association between periodontal disease and patients with liver diseases associated with hepatitis c virus (hcv) and/or hepatitis b virus (hbv) infection. |
| PubMedID- 21057160 | Twenty-one patients (62%) had liver disease associated with hepatitis c virus (hcv) and 5 patients with hepatitis b virus (62%). |
| PubMedID- 25716364 | Functional and morphological myocardial changes in hepatitis c virus patients with end-stage liver disease. |
| PubMedID- 25320839 | Background: heavy alcohol use has been hypothesized to accelerate disease progression to end-stage liver disease in patients with hepatitis c virus (hcv) infection. |
| PubMedID- 23874824 | Among the main causes of liver disease, co-infection with the hepatitis c (hcv) or hepatitis b (hbv) virus is the most frequent and has the worst prognosis [3]. |
| PubMedID- 21809486 | The purpose of this study was to determine the serum level of oxidized low-density lipoprotein (ox-ldl), and evaluate its association with different clinically valuable parameters of liver disease in patients with chronic hepatitis c. |
| PubMedID- 23707779 | Dietary cholesterol intake is associated with progression of liver disease in patients with chronic hepatitis c: analysis of the hepatitis c antiviral long-term treatment against cirrhosis trial. |
| PubMedID- 23763386 | Aim: in chronic liver disease associated with hepatitis c virus (hcv), a low platelet count is a major obstacle in carrying out interferon (ifn) treatment. |
| PubMedID- 25457210 | Background & aims: genetic variants of patatin-like phospholipase domain-containing 3 (pnpla3) and diabetes are associated with liver disease severity, in patients with chronic hepatitis c (chc) infection. |
| PubMedID- 23869664 | Progression of liver disease is common with hepatitis c virus (hcv) infection and known to be accelerated in the presence of hiv 4,5. according to current guidelines, all coinfected patients with chronic hcv infection and significant fibrosis (≥f2) should be considered for hcv therapy given their increased risk of death from liver disease 6,7. hcv treatment should preferentially be offered to patients with controlled hiv infection, and therefore it is recommended when cd4 cell counts are above 350 cells/μl and often deferred when counts are below 200 cells/μl 7. however, patients with cd4 cell counts below 200 cells/μl have been shown to respond well to hcv treatment when hiv replication is suppressed 8. despite these recommendations, the extent to which hiv/hcv-coinfected patients start hcv therapy is not well documented in europe. |
| PubMedID- 25848478 | However, chronic hepatitis c is associated with a higher liver disease related cardiovascular and all-cause mortality of hd patients. |
| PubMedID- 23241078 | The economic burden of advanced liver disease among patients with hepatitis c virus: a large state medicaid perspective. |
| PubMedID- 25961570 | Reduced expression of ifnar1 has also been observed in the liver biopsies of chronic liver disease patients with hepatitis c virus infection [40]. |
| PubMedID- 21188525 | Dietary history and physical activity and risk of advanced liver disease in veterans with chronic hepatitis c infection. |
| PubMedID- 23311684 | Problem drug users are at high risk of liver disease resulting from hepatitis c virus (hcv) infection because of its high prevalence in this population [7]. |
| PubMedID- 26125137 | Low cross-neutralization of hepatitis c correlates with liver disease in immunocompromized patients. |
| PubMedID- 21145859 | Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis c patients with minimal liver disease. |
| PubMedID- 23630437 | Status of essential trace minerals and oxidative stress in viral hepatitis c patients with nonalcoholic fatty liver disease. |
| PubMedID- 25400432 | Chronic liver disease including hepatitis c virus (hcv) infection is one of the main cause for the development of hepatic angiogenesis and thereby plays a critical role in the modulation of hepatic angiogenesis that finally leads to hepatocellular carcinoma progression and invasion. |
Page: 1 2